Rib-X Pharmaceuticals, Inc. Presents Data Demonstrating Potent In Vitro Activity of Delafloxacin Against Drug-Resistant Gonorrhea
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
VIENNA--(BUSINESS WIRE)--Today, Rib-X Pharmaceuticals, Inc. presented in vitro data on the potent activity of delafloxacin against drug-resistant strains of Neisseria gonorrhoeae (gonorrhea). Delafloxacin is an investigational novel fluoroquinolone antibiotic with intravenous (IV) and oral formulations. These data were presented today at the STI & AIDS World Congress 2013 in Vienna, Austria (poster P2.197, Clinical Sciences Track). Rib-X Pharmaceuticals is also evaluating delafloxacin in the ongoing Phase 3 PROCEED (PROve Clinical Efficacy and Effect of Delafloxacin) study in patients with acute bacterial skin and skin structure infections (ABSSSI).
Help employers find you! Check out all the jobs and post your resume.
VIENNA--(BUSINESS WIRE)--Today, Rib-X Pharmaceuticals, Inc. presented in vitro data on the potent activity of delafloxacin against drug-resistant strains of Neisseria gonorrhoeae (gonorrhea). Delafloxacin is an investigational novel fluoroquinolone antibiotic with intravenous (IV) and oral formulations. These data were presented today at the STI & AIDS World Congress 2013 in Vienna, Austria (poster P2.197, Clinical Sciences Track). Rib-X Pharmaceuticals is also evaluating delafloxacin in the ongoing Phase 3 PROCEED (PROve Clinical Efficacy and Effect of Delafloxacin) study in patients with acute bacterial skin and skin structure infections (ABSSSI).
Help employers find you! Check out all the jobs and post your resume.